Humana slumps as data shows membership in high-rating Medicare plans declined
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Piper Sandler Downgrades Humana (HUM) to Neutral
October 3, 2024 9:35 AM EDTPiper Sandler analyst Jessica Tassan downgraded Humana (NYSE: HUM) from Overweight to Neutral with a price target of $274.00 (from $392.00).
The analyst comments "HUM published an 8K indicating only 1.6M, or 25%, of the company's MA/ SNP members are enrolled in plans rated 4.0+ Stars for 2025.... More
Raymond James Reiterates Market Perform Rating on Humana (HUM)
October 3, 2024 6:17 AM EDTRaymond James analyst John Ransom reiterated a Market Perform rating and {REMOVEPT} price target on Humana (NYSE: HUM).
The analyst comments "HUM management hosted a call at noon today for the sell side, and the stock had a modest bounce from the initial sell-off, likely due to the not-zero chance that their appeal to CMS might succeed and that there are not zero offsets, including more TBC flexibility and the ability to migrate group MA members to a 4.5 Star plan. At the current price of $247/share (down ~$150 from the recent peak), we... More
Wells Fargo Reiterates Overweight Rating on Humana (HUM)
October 3, 2024 5:55 AM EDTWells Fargo analyst Stephen Baxter reiterated an Overweight rating and $387.00 price target on Humana (NYSE: HUM)
The analyst comments "Analysis of Plan Finder. Our review of Medicare Plan Finder suggested that contracts H5216, H5619, H6622, H0028, and H5525 were potentially at risk if filtering functionality was indicative of actual results. Of the... More
Bernstein SocGen Group Reiterates Market Perform Rating on Humana (HUM)
October 3, 2024 5:52 AM EDTBernstein SocGen Group analyst Lance Wilkes reiterated a Market Perform rating and $405.00 price target on Humana (NYSE: HUM)
The analyst comments "Yesterday HUM issued a press release outlining their MA offerings for 2025, which was marketing like in tone, presenting how attractive the plans are for... More
Barclays Takeaways from Humana (HUM) Mgmt Call
October 2, 2024 1:23 PM EDTBarclays analyst Andrew Mok reiterated an Overweight rating and $364.00 price target on Humana (NYSE: HUM)
The analyst comments "Initial HUM Call Takeaways: At noon today, HUM hosted a group conference call with the sellside to take questions over the loss of its bonus star ratings. See below for our raw notes: HUM Participants Include: CEO Jim Rechtin, CFO Susan Diamond, and President of Medicare & Medicaid George Renaudin, and Vice President of IR Lisa Stoner Jim Rechtin Comments: Goes without saying -> disappointed with results Too much concentration in a specific contract (5216) -> will... More
Morgan Stanley Reiterates Equal-weight Rating on Humana (HUM)
October 2, 2024 12:45 PM EDTMorgan Stanley analyst Erin Wright reiterated an Equal-weight rating and $374.00 price target on Humana (NYSE: HUM).
The analyst comments "What happened? HUM Disclosed a Meaningful Reduction in 4+ Star Plan Members (PY26) to 25% (from 94%) Driven, in part, by Largest Contract (H5216). HUM released an... More
JPMorgan on Humana (HUM): 'We believe that HUM will need to speak to the general impact of the potential reduction in stars for 2026'
October 2, 2024 10:49 AM EDTJPMorgan analyst Lisa Gill reiterated a Neutral rating and $396.00 price target on Humana (NYSE: HUM).
The analyst comments "This morning, HUM announced that, based on preliminary data from CMS (we wrote about an issue with Plan Finder potentially revealing star ratings), it expected 1.6M members (or roughly 25%) currently enrolled in plans that will be in 4+ star rated plans for 2025, down from 94% in 2024. A large driver, as we wrote about yesterday, is the H5216 contract which has ~45% of HUMs MA membership and preliminary data suggests will step down to 3.5 stars in 2025 from 4.5 stars in 2024.... More
BTIG Comments on Humana (HUM)
October 2, 2024 9:52 AM EDTBTIG Comments on Humana (NYSE: HUM)
The analyst comments "This morning, 10/2/24 BMO, Humana (HUM, Not Rated) filed an 8K announcing a significant expected decline in the number of members that will be enrolled in an MA plan rated 4 Stars and above for 2025. The filing comes after the stock traded down ~12% yesterday. Preliminary 2025 MA Star Ratings data provided by CMS shows that as of 10/1/24, HUM has... More
Mizuho Trade Desk Comments on 'Supernova' Blowup at Humana (HUM): 'it is very likely the financials are impaired especially into FY26'
October 2, 2024 8:41 AM EDTMizuho Trade Desk Comments on 'Supernova' Blowup at Humana (NYSE: HUM): 'it is very likely the financials are impaired especially into FY26'
The analyst comments "HUM is currently trading lower by 20% following preliminary 2025 Medicare Advantage Star Ratings data from CMS. The drop in STARS we would argue is far worse than even bearish investors believed would be the outcome as the Company is reporting only 25% of its members are enrolled in plans rated 4-stars and above, down from 95% headed into this calendar year. Though the Company is asserting it narrowly... More
